Echo Pharmaceuticals is a technology-based pharmaceutical drug development company, with a patented drug delivery technology, Alitra™, to formulate lipophilic active drug candidates into optimal delivery systems and innovative medicines suitable for clinical trials.
The advanced technology platform for the extraction, purification, formulation and encapsulation of active pharmaceutical ingredients (API's) with a lipophilic character, has been used for the development of the innovative medicine Namisol®.
The advanced technologies can be accomplished through contract research or contract manufacturing. The patented technologies for processing lipophilic compounds can also be licensed out for the formulation of ameliorated drug delivery. Echo Pharmaceuticals was established in 2006, and has extensive expertise in cannabinoid science, which ensures the supply of high quality analytical standards for pharmaceutical research and the development of evolutionary medicines.
Our technologies:
- The drug delivery technology, Alitra™
- Formulation technology, to process lipophilic active compounds
- Isolation technology, extraction and purification of active drug candidates
- Analytical cannabinoid standards for R&D
The drug delivery technology Alitra™ - An emulsifying technology to enhance the bioavailability of lipophilic compounds
A large amount of targeted molecules resulting from pharmaceutical research have a lipophilic character. Lipophilic compounds dispose of poor water solubility and therefore enter the bloodstream with difficulty. The patented drug delivery technology Alitra™ improves the absorption and bioavailability of lipophilic Active Pharmaceutical Ingredients (API's) after in-vivo administration, facilitating them to reach the pharmaceutical site of action.
The drug delivery technology (DDT) Alitra™ is an emulsifying technology that significantly improves the uptake and solubility of compounds with a lipophilic character into the bloodstream. Alitra™ has the great advantage of using significantly less surfactant than existing formulation technologies. The minimised use of surfactant has cost-effective and safety benefits for production companies and medical subjects. Advantages of Alitra™ The formulation technology has been created such that the optimal final pharmaceutical dosage form:
|  |
NAMISOL® - A successful implementation of Alitra™
The implementation of the drug delivery technology Alitra™ has resulted in the optimal application Namisol®. Namisol® contains the lipophilic active ingredient Dronabinol, that has a therapeutic effect mainly on the central nervous system (CNS). Current applications of the cannabinoid-based tablet Namisol® for the treatment of pain and spasms in MS patients, patients with Alzheimer's Disease and patients with chronic pain are being investigated.
Additional technologies and opportunities:
Formulation technology - To process lipophilic active compounds
The specialised equipment, years of experience and skills of our team, perform small- scale test runs in a cGMP environment to formulate a selected API into a suitable application form using encapsulation, granulation via conventional methods, or Supercritical Carbon Dioxide (CO2) Technology. Pharmaceutical drug delivery programmes for required dosage forms are performed according to the client's needs.
Isolation technology - Extraction and purification of active drug candidates
Echo Pharmaceuticals' proprietary knowledge and competence is in the extraction and purification of arbitrary API's from plant materials or other synthetic matrixes. Isolation takes place under controlled laboratory conditions, assuring a constant quality of the purified API.
An application for this technology has resulted in a variety of high-quality isolated cannabinoids that are applied as analytical standards or as cannabinoid standards for clinical trials.
Cannabinoids - Analytical standards for research & development
Echo Pharmaceuticals offers a wide range of cannabinoids as analytical standards produced from mg to g quantities at the required degree of purity. Isolation takes place under controlled laboratory conditions, assuring the quality of the purified cannabinoid. Additionally delta9-THC can be supplied as drug substance for clinical trial use, produced according to cGMP guidelines.
Contract Research & Manufacturing
The pharmaceutical product development programme starts by isolating, then formulating the isolated API or other drug candidate, followed by the production of clinical batches in our cGMP facilities. We provide guidance and perform research throughout the programme or in any of the drug development stages, as required. All activities are performed in our designated facilities, which operate in a GMP environment. Echo performs small-scale test runs under cGMP conditions.
Licensing
The patented technologies for processing lipophilic compounds can be licensed out for the formulation of optimised drug delivery systems or the production of innovative medicine developments.
For more information please contact:
Echo Pharmaceuticals B.V.
Headquarters & Innovation Center in Nijmegen
Clinical Research Center
Jonkerbosplein 52
14e/Unit A1
6534AB Nijmegen
The Netherlands
Isolation & Formulation Technology Center
Rijnkade 16A
1382 GS in Weesp
The Netherlands
Tel: +31 (0)294 457 353
info@echo-pharma.com
www.echo-pharma.com
Fields marked * are compulsory
Related Intelligence and Suppliers
Echo Pharmaceuticals White Papers
Latest Echo Pharmaceuticals Products
Drug Delivery Suppliers
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
